Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$146.82
-1.2%
$155.47
$143.13
$175.97
$357.93B0.537.66 million shs7.59 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$106.18
-2.5%
$102.15
$62.55
$142.79
$41.68B1.623.00 million shs2.80 million shs
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
$137.47
+0.5%
$129.71
$59.37
$141.70
$35.10B2.522.79 million shs5.65 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.15%+0.74%-5.75%-7.96%-9.72%
Moderna, Inc. stock logo
MRNA
Moderna
-2.45%+4.10%-1.15%+4.29%-18.77%
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
+0.58%+7.70%+0.45%+11.35%+130.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.933 of 5 stars
3.23.04.23.93.62.51.9
Moderna, Inc. stock logo
MRNA
Moderna
4.0179 of 5 stars
3.12.00.04.61.83.30.6
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
4.5686 of 5 stars
2.52.00.03.43.22.53.8

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8619.78% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.25
Hold$126.4919.12% Upside
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
2.94
Moderate Buy$136.94-0.38% Downside

Current Analyst Ratings

Latest JNJ, MRNA, and RCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/17/2024
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$164.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/11/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/11/2024
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$150.00 ➝ $154.00
4/9/2024
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
4/1/2024
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.15$13.51 per share10.87$28.57 per share5.14
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B5.94N/AN/A$36.33 per share2.92
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
$13.90B2.54$13.31 per share10.33$19.12 per share7.19

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.1513.432.4545.26%36.43%15.01%7/18/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Confirmed)
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
$1.70B$6.2222.1011.740.5012.22%45.55%5.47%5/29/2024 (Estimated)

Latest JNJ, MRNA, and RCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.36N/A+$3.36N/AN/AN/A  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
2/1/2024Q4 23
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
$1.13$1.25+$0.12$1.44$3.36 billion$3.33 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.24%+5.70%29.68%63 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
N/AN/AN/AN/AN/A

Latest JNJ, MRNA, and RCL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
4.03
0.19
0.16

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
87.53%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
8.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million322.77 millionOptionable
Royal Caribbean Cruises Ltd. stock logo
RCL
Royal Caribbean Cruises
98,200256.68 million234.35 millionOptionable

JNJ, MRNA, and RCL Headlines

SourceHeadline
A Look At Forward Guidance Issued by Royal Caribbean Cruises Ltd. (RCL) Within Their SEC 10-Q FilingA Look At Forward Guidance Issued by Royal Caribbean Cruises Ltd. (RCL) Within Their SEC 10-Q Filing
americanbankingnews.com - April 26 at 4:06 AM
Q3 2025 EPS Estimates for Royal Caribbean Cruises Ltd. (NYSE:RCL) Reduced by Zacks ResearchQ3 2025 EPS Estimates for Royal Caribbean Cruises Ltd. (NYSE:RCL) Reduced by Zacks Research
americanbankingnews.com - April 26 at 3:32 AM
Cruise Boom: Royal Caribbean Lifts Profit View AgainCruise Boom: Royal Caribbean Lifts Profit View Again
marinelink.com - April 26 at 1:42 AM
Buy Rating Affirmed for Royal Caribbean with Target Price Increase Amidst Strong Performance and Strategic GrowthBuy Rating Affirmed for Royal Caribbean with Target Price Increase Amidst Strong Performance and Strategic Growth
markets.businessinsider.com - April 25 at 8:41 PM
Why Carnival, Royal Caribbean dont offer key entertainment optionWhy Carnival, Royal Caribbean don't offer key entertainment option
msn.com - April 25 at 8:41 PM
Royal Caribbean Cruises (RCL) Q1 2024 Earnings Call TranscriptRoyal Caribbean Cruises (RCL) Q1 2024 Earnings Call Transcript
fool.com - April 25 at 8:41 PM
State of New Jersey Common Pension Fund D Purchases 6,713 Shares of Royal Caribbean Cruises Ltd. (NYSE:RCL)State of New Jersey Common Pension Fund D Purchases 6,713 Shares of Royal Caribbean Cruises Ltd. (NYSE:RCL)
marketbeat.com - April 25 at 7:10 PM
Royal Caribbean sees record bookings as demand for experiences and travel growRoyal Caribbean sees record bookings as demand for experiences and travel grow
msn.com - April 25 at 3:39 PM
Royal Caribbean (RCL) Tops Q1 Earnings Estimates, Ups 24 ViewRoyal Caribbean (RCL) Tops Q1 Earnings Estimates, Ups '24 View
zacks.com - April 25 at 3:01 PM
Royal Caribbean Cruises Non-GAAP EPS of $1.77, revenue of $3.7BRoyal Caribbean Cruises Non-GAAP EPS of $1.77, revenue of $3.7B
msn.com - April 25 at 10:38 AM
Royal Caribbean Cruises Ltd. Q1 Earnings SummaryRoyal Caribbean Cruises Ltd. Q1 Earnings Summary
markets.businessinsider.com - April 25 at 10:38 AM
Royal Caribbean (NYSE:RCL) Surprises With Q1 SalesRoyal Caribbean (NYSE:RCL) Surprises With Q1 Sales
finance.yahoo.com - April 25 at 10:38 AM
Royal Caribbean’s stock rallies toward a record on ‘very robust’ cruise demandRoyal Caribbean’s stock rallies toward a record on ‘very robust’ cruise demand
msn.com - April 25 at 10:38 AM
Royal Caribbean Surpasses Analyst EPS Estimates and Boosts Full-Year Guidance Amid Strong DemandRoyal Caribbean Surpasses Analyst EPS Estimates and Boosts Full-Year Guidance Amid Strong Demand
finance.yahoo.com - April 25 at 10:38 AM
Royal Caribbean Climbs In Buy Zone, Hikes Outlook On Strong DemandRoyal Caribbean Climbs In Buy Zone, Hikes Outlook On Strong Demand
finance.yahoo.com - April 25 at 10:38 AM
Royal Caribbean Earnings Tick All the Boxes. The Stock Is Sailing Higher.Royal Caribbean Earnings Tick All the Boxes. The Stock Is Sailing Higher.
finance.yahoo.com - April 25 at 10:38 AM
Compared to Estimates, Royal Caribbean (RCL) Q1 Earnings: A Look at Key MetricsCompared to Estimates, Royal Caribbean (RCL) Q1 Earnings: A Look at Key Metrics
zacks.com - April 25 at 10:36 AM
Royal Caribbean Cruises (NYSE:RCL) Releases Q2 2024 Earnings GuidanceRoyal Caribbean Cruises (NYSE:RCL) Releases Q2 2024 Earnings Guidance
marketbeat.com - April 25 at 10:28 AM
Zacks Research Research Analysts Lower Earnings Estimates for Royal Caribbean Cruises Ltd. (NYSE:RCL)Zacks Research Research Analysts Lower Earnings Estimates for Royal Caribbean Cruises Ltd. (NYSE:RCL)
marketbeat.com - April 25 at 8:47 AM
Royal Caribbean (RCL) Q1 Earnings and Revenues Surpass EstimatesRoyal Caribbean (RCL) Q1 Earnings and Revenues Surpass Estimates
zacks.com - April 25 at 8:41 AM
ROYAL CARIBBEAN GROUP REPORTS FIRST QUARTER RESULTS AND INCREASES FULL YEAR GUIDANCE ON CONTINUED STRONG DEMANDROYAL CARIBBEAN GROUP REPORTS FIRST QUARTER RESULTS AND INCREASES FULL YEAR GUIDANCE ON CONTINUED STRONG DEMAND
prnewswire.com - April 25 at 6:30 AM
Q2 2024 Earnings Forecast for Royal Caribbean Cruises Ltd. (NYSE:RCL) Issued By Zacks ResearchQ2 2024 Earnings Forecast for Royal Caribbean Cruises Ltd. (NYSE:RCL) Issued By Zacks Research
americanbankingnews.com - April 25 at 1:42 AM
Royal Caribbean Stock Can Cruise Higher After Earnings. What Investors Need to Hear.Royal Caribbean Stock Can Cruise Higher After Earnings. What Investors Need to Hear.
barrons.com - April 24 at 4:00 PM
Royal Caribbean (RCL) To Report Earnings Tomorrow: Here Is What To ExpectRoyal Caribbean (RCL) To Report Earnings Tomorrow: Here Is What To Expect
finance.yahoo.com - April 24 at 9:36 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Royal Caribbean Cruises logo

Royal Caribbean Cruises

NYSE:RCL
Royal Caribbean Cruises Ltd. operates as a cruise company worldwide. The company operates cruises under the Royal Caribbean International, Celebrity Cruises, and Silversea Cruises brands, which comprise a range of itineraries. As of February 21, 2024, it operated 65 ships. Royal Caribbean Cruises Ltd. was founded in 1968 and is headquartered in Miami, Florida.